GHRP-2

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that has been the subject of more clinical research than almost any other GHRP. Also known by its pharmaceutical name Pralmorelin, GHRP-2 has been investigated in multiple clinical settings including growth hormone deficiency diagnosis, therapeutic GH optimization in adults, and pediatric growth disorders. In Japan, it received regulatory approval as a diagnostic agent for assessing GH secretory capacity — making it one of the few GHRPs with actual regulatory authorization in a major market.

GHRP-2 occupies a useful middle ground in the GHRP spectrum. It is more potent than Ipamorelin for acute GH release, but less so than Hexarelin. More importantly, it desensitizes more slowly than Hexarelin — making it more practical for sustained use protocols. The cortisol and prolactin elevations it produces are moderate: meaningfully greater than Ipamorelin's near-zero hormonal side noise, but substantially less than the elevations seen with Hexarelin. For most users, the cortisol bump is transient and manageable, particularly when dosing is kept to 2x rather than 3x daily.

The appetite-stimulating effect of GHRP-2 is an important characteristic to understand. Like other GHRPs that activate the ghrelin pathway, GHRP-2 can produce notable hunger — typically within 20–40 minutes of injection. This occurs because ghrelin is the body's primary hunger hormone, and GHRP-2's receptor activity partially overlaps with ghrelin's natural hunger-signaling function. This is not considered a side effect in contexts where caloric intake needs to be increased (muscle-building phases), but it's an important consideration for anyone using GHRP-2 during caloric restriction or fat-loss protocols.

From a research evidence standpoint, GHRP-2 is arguably the most thoroughly documented GHRP in the literature. Decades of published studies have characterized its receptor pharmacology, dose-response curves, safety profile across age groups, interactions with other hormonal systems, and downstream effects on IGF-1, muscle metabolism, and fat oxidation. For practitioners and researchers who prefer the most extensively studied option, GHRP-2's evidence base is a significant advantage.